Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

55.95USD
25 Jul 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$55.95
Open
--
Day's High
--
Day's Low
--
Volume
99
Avg. Vol
7,930,431
52-wk High
$76.80
52-wk Low
$46.01

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb’s Orencia receives second European Commission approval
6:59am EDT 

July 26 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers Squibb’S Orencia (abatacept) receives second European Commission approval in less than a year – new approval for treatment of active psoriatic arthritis (PSA)1.Approval was based on results from two randomized, double-blind, placebo-controlled studies PSA-i and PSA-ii.  Full Article

FDA accepts Bristol-Myers Squibb's applications for Opdivo
Monday, 24 Jul 2017 04:15pm EDT 

July 24 (Reuters) - Bristol-Myers Squibb Co :U.S. Food And Drug Administration accepts Bristol-Myers Squibb’s applications for Opdivo (nivolumab) four-week dosing schedule across all approved indications.Bristol-Myers Squibb Co - ‍applications are under review with an action date of March 5, 2018​.Bristol-Myers - ‍in separate Phase 3 study of Yervoy 3 mg/kg, 1 case of fatal Guillain-Barré syndrome were reported​.Bristol-Myers - ‍in separate Phase 3 study of Yervoy 3 mg/kg, also 1 case of severe (grade 3) peripheral motor neuropathy were reported​.  Full Article

Bristol-Myers Squibb says Yervoy showed a consistent safety profile and comparable drug levels across pediatric and adult patients​
Monday, 24 Jul 2017 06:59am EDT 

July 24 (Reuters) - Bristol-myers Squibb Co :U.S. Food and Drug Administration expands approval of Yervoy (ipilimumab) to include pediatric patients 12 years and older with unresectable or metastatic melanoma.Bristol-Myers Squibb Co - Yervoy showed a consistent safety profile and comparable drug levels across pediatric and adult patients​.  Full Article

Exelixis, Bristol-Myers Squibb initiate phase 3 trial
Monday, 10 Jul 2017 08:00am EDT 

July 10 (Reuters) - Bristol-myers Squibb Co ::Exelixis and Bristol-Myers Squibb initiate phase 3 trial of opdivo in combination with cabometyx or opdivo and yervoy in combination with cabometyx, versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma.Bristol-Myers Squibb Co - ‍exelixis, Bristol-Myers Squibb and Ipsen to co-fund trial​.Bristol-Myers Squibb Co - ‍checkmate 9ER is an open-label, randomized, multi-national phase 3 trial that aims to enroll approximately 1,014 patients​.  Full Article

FDA accepts for priority review Bristol-Myers Squibb's application for sprycel
Monday, 10 Jul 2017 06:58am EDT 

July 10 (Reuters) - Bristol-Myers Squibb Co ::U.S. Food and Drug Administration accepts for priority review Bristol-Myers Squibb's application for sprycel (dasatinib) in children with philadelphia chromosome-positive chronic phase chronic myeloid leukemia.U.S. Food and Drug Administration accepts for priority review Bristol-Myers Squibb's application for sprycel (dasatinib) in children with philadelphia chromosome-positive chronic phase chronic myeloid leukemia.Bristol-Myers Squibb Co - ‍submission includes powder for oral suspension formulation​.Bristol-Myers Squibb Co- ‍application is under priority review with an action date of November 9, 2017​.  Full Article

Bristol-Myers Squibb's Orencia receives FDA approval
Thursday, 6 Jul 2017 07:30am EDT 

July 6 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers Squibb's Orencia (abatacept) receives FDA approval for treatment of active psoriatic arthritis (PSA) in adults.Bristol-Myers Squibb Co - Orencia is approved and available in both intravenous and subcutaneous injection formulations.  Full Article

Bristol-Myers Squibb announces expiration of cash tender offer
Wednesday, 21 Jun 2017 06:59am EDT 

June 21 (Reuters) - Bristol-Myers Squibb Co ::Bristol-Myers Squibb announces the expiration of its cash tender offer.Bristol-Myers Squibb announces the expiration of its cash tender offer.Bristol-Myers -approximately $337.0 million in aggregate principal amount of notes subject to tender offer were validly tendered and not validly withdrawn.  Full Article

Bristol-Myers announces results from extended follow-up data evaluating opdivo
Friday, 16 Jun 2017 06:58am EDT 

June 16 (Reuters) - Bristol-Myers Squibb Co ::Extended follow-up data evaluating opdivo (nivolumab) shows durable response in adult patients with relapsed or progressed classical hodgkin lymphoma.Bristol-Myers Squibb- ‍results show overall response rates of 65%/greater with median follow-up of at least 16 months.Bristol-Myers says as per extended follow-up data evaluating opdivo​, ‍across cohorts, median overall survival not reached, 40% of patients remained on treatment.  Full Article

Bristol-Myers Squibb to sell manufacturing facility to SK Biotek Co
Friday, 16 Jun 2017 04:35am EDT 

June 16 (Reuters) - Bristol-Myers Squibb Co : :Bristol-Myers Squibb to sell manufacturing facility in swords, Ireland to SK Biotek Co., Ltd..Bristol-Myers - to sell small molecule active pharmaceutical ingredient manufacturing facility in swords, Ireland, to SK Biotek.Bristol-Myers Squibb Co - transaction has been approved by boards of directors of both companies.  Full Article

Bristol-Myers Squibb announces cash tender offer
Wednesday, 14 Jun 2017 08:40am EDT 

June 14 (Reuters) - Bristol-myers Squibb Co :Announces cash tender offer for any and all of certain of its outstanding debt securities.Commenced a cash tender offer for any and all of its 5.875 pct notes due 2036, 6.125 pct notes due 2038 and 6.875 pct debentures due 2097.Expiration date of tender offer is 5:00 p.m., New York City time, on June 20, 2017.  Full Article

BRIEF-Bristol-Myers Squibb’s Orencia receives second European Commission approval

* Bristol-Myers Squibb’S Orencia (abatacept) receives second European Commission approval in less than a year – new approval for treatment of active psoriatic arthritis (PSA)1